Eloxx Pharmaceuticals, Inc. cash flow to debt ratio of -632.70% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Eloxx Pharmaceuticals, Inc.'s free cash flow has increased 100.00% from $-4.71M last year to $0.00, signaling increasing performance

Eloxx Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Eloxx Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from -0.27 last year to 0.00 today, signaling weakened financials

Eloxx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Eloxx Pharmaceuticals, Inc.'s interest coverage ratio is -222.84, which means that the company struggles to meet interest obligations, signaling financial risk.

Eloxx Pharmaceuticals, Inc.'s profit margin was -49.43% last year and is 0.00% this year, signaling increasing performance

Eloxx Pharmaceuticals, Inc.'s short-term liabilities of $17.18M exceed its short-term assets of $5.27M, signaling financial risk

Eloxx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eloxx Pharmaceuticals, Inc.'s return on equity of -42.52%, is lower than 15.00%, indicating bad performance

Eloxx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eloxx Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Eloxx Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Eloxx Pharmaceuticals, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eloxx Pharmaceuticals, Inc.'s yearly earnings has decreased 90.74% since last year from $-3.14M to $-6.00M, signaling decreasing performance

Eloxx Pharmaceuticals, Inc.'s yearly revenue has decreased 100.00% since last year from $6.36M to $0.00, signaling decreasing performance

ROIC -17.76% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Eloxx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Eloxx Pharmaceuticals, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Eloxx Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Eloxx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. has a price-to-book ratio of 2.20x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Eloxx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue